Logo

DNAnexus: Thomas Laur, Richard Daly

Sep 12, 2023

DNAnexus has named Thomas Laur as CEO and a member of the board of directors. He succeeds Richard Daly, who had led the genomic analysis software firm since 2013. Daly remains on the board and will continue to serve as an active advisor, the company said. Laur has more than 25 years of experience in healthcare software and technology services, most recently as executive VP and president of the technology-enabled services division at Change Healthcare, which merged with UnitedHealth Group's Optum a year ago. Previously, he was president of SAP's healthcare division.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.